The influence of omalizumab (Xolair ) on the composition of intracellular granules and Degranulationsschwelle of skin mast cells and peripheral basophils before and during omalizumab therapy in patients with chronic urticaria - OTTO

niversitätsklinikum MagdeburgDekan0 个研究点目标入组 24 人开始时间: 2011年10月12日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•intermittent or persistent symptoms of chronic urticaria and / or angioedema for at least 6 weeks to treat refractory stage 3 of the international guideline CU, or
•- Persistent symptoms of AD with / without allergic / s asthma despite treatment with topical steroids drug class two and systemic therapy with antihistamines.
•- The / the patient / in is able to understand the study, to give his / her consent and is available for the study duration.
•- Written consent after thorough verbal and written explanation is given.

•- Hypersensitivity to omalizumab or Xolair one of the ingredients.
•- Xolair therapy in history
•- Immunosuppressive medication 4 weeks before study entry
•- Acute asthma exacerbations, acute bronchospasm, status asthmaticus
•- Pregnancy
•- Severe other diseases: for example HIV, chronic hepatitis B / C, severe autoimmune disease or with pre-existing renal or hepatic dysfunction.
•- Non-compliance and / or inability to understand the context in the study required information.

发起方

niversitätsklinikum MagdeburgDekan